Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Breast cancer—advanced stage: “cure—still a long way to go?”

Breast cancer—advanced stage: “cure—still a long way to go?” editorial memo (2012) 5:85–86 DOI 10.1007/s12254-012-0022-3 Breast cancer—advanced stage: “cure—still a long way to go?” Herbert Stöger Received: 8 May 2012 / Accepted: 14 May 2012 / Published online: 5 June 2012 © Springer-Verlag Wien 2012 Herbert Stöger Metastatic breast cancer (MBC) remains essentially in- There is no single standard of care for patients with curable, and goals of therapy include the palliation of MBC, as treatment plans require an individualized symptoms, delay of disease progression, and prolongati- approach based on multiple factors. These include speci- on of overall survival time without negatively impacting fic tumor biology, growth rate of disease, presence of vis- quality of life. Though numerous randomized clinical ceral metastases, history of prior therapy and response, trials have shown improvements in overall response ra- risk for toxicity, and patient preference. Targeted biologic tes, few have found clear survival benefits. In recent ye- therapies offer an entirely new treatment dimension for ars, however, there has been a small but growing series patients with MBC. With targeted biologics, such as tras- of clinical trials demonstrating modest, but meaningful tuzumab, the potential for enhanced or synergistic acti- survival advantages in metastatic disease [1]. In addi- vity is a compelling argument http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Breast cancer—advanced stage: “cure—still a long way to go?”

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/breast-cancer-advanced-stage-cure-still-a-long-way-to-go-jtda46Dr9u
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0022-3
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2012) 5:85–86 DOI 10.1007/s12254-012-0022-3 Breast cancer—advanced stage: “cure—still a long way to go?” Herbert Stöger Received: 8 May 2012 / Accepted: 14 May 2012 / Published online: 5 June 2012 © Springer-Verlag Wien 2012 Herbert Stöger Metastatic breast cancer (MBC) remains essentially in- There is no single standard of care for patients with curable, and goals of therapy include the palliation of MBC, as treatment plans require an individualized symptoms, delay of disease progression, and prolongati- approach based on multiple factors. These include speci- on of overall survival time without negatively impacting fic tumor biology, growth rate of disease, presence of vis- quality of life. Though numerous randomized clinical ceral metastases, history of prior therapy and response, trials have shown improvements in overall response ra- risk for toxicity, and patient preference. Targeted biologic tes, few have found clear survival benefits. In recent ye- therapies offer an entirely new treatment dimension for ars, however, there has been a small but growing series patients with MBC. With targeted biologics, such as tras- of clinical trials demonstrating modest, but meaningful tuzumab, the potential for enhanced or synergistic acti- survival advantages in metastatic disease [1]. In addi- vity is a compelling argument

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 5, 2012

References

  • The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
    Chia, SK; Speers, CH; D’yachkova, Y
  • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    Slamon, DJ; Leyland-Jones, B; Shak, S
  • Long term follow-up of patients with complete remission following chemotherapy for metastatic breast cancer
    Greenberg, PA; Hortobagyi, GN; Smith, TL
  • Is breast cancer survival improving?
    Giordano, SH; Buzdar, AU; Smith, TL
  • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Baselga, J; Cortés, J; Kim, SB